Key facts
- It has raised $8.3M; the latest was Seed Round ($8.3M) in Feb 2025.
- Notable investors include High-Tech Gründerfonds, BMH Beteiligungs-Managementgesellschaft Hessen, Bruker, CARMA FUND Management, Hessen Kapital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Akribion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Akribion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akribion Therapeutics
Operator of a biotechnology company intended to develop RNA-guided, nuclease-based technology for programmable cell depletion. The company's gene editing platform can kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed, enabling healthcare professionals to quickly adapted the platform to target different cells, making it much faster to develop new treatments compared to traditional methods.
- Sector
- Healthcare
- HQ
- Zwingenberg, Germany
- Founded
- 2023
- Employees
- 16
- Website
- akribion-therapeutics.com/
- Ownership
- Privately Held (backing)
Akribion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akribion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akribion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.